New developments in the adjuvant therapy of stage II colon cancer. Risk assessments in the older patient.
While adjuvant chemotherapy has proven benefit in stage III colon cancer, its role for stage II colon cancer remains unclear. This article reviews data regarding adjuvant therapy in stage II colon cancer. We will discuss factors to consider in assessing the risk of recurrence in stage II disease. We will also outline considerations regarding adjuvant therapy in older patients.
McCleary
Nadine Jackson
NJ
Department of Medical Oncology, Gastrointestinal Cancer Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. najackson@partners.org
Meyerhardt
Jeffrey A
JA
D000368:Aged; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment